As patent cliff levels off, biosimilars offer opportunity

09/11/2013 | Drug Store News

About $86 billion worth of branded drugs will lose patent protection between 2013 and 2017, compared with $101 billion worth of drugs that lost patent protection between 2008 and 2012, according to IMS. Biologic drugs losing patent protection may present an opportunity for other drugmakers to gain market share, but some U.S. states have passed laws restricting substitution of biosimilar drugs.

View Full Article in:

Drug Store News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
European Sales Manager
SentreHEART, Inc.
Germany, Benelux, UK
REG AFFAIRS PROJ MGR - 1400000A7F
Abbott
San Jose, CA
SPECIALIST II SYSTEMS INTEGRATION - 140000033P
Abbott
Dallas, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD